Menopause Period Skin Changes and Longevity Protocol — Pre/Peri/Post-Menopause Clinical Guide 2026

Menopause is not only the end of the reproductive period biologically; it is a comprehensive transition period in terms of skin, bone, cardiovascular system, and metabolic integrity. In my clinical practice, a significant portion of female patients experience skin changes "suddenly" in the last 5 years before menopause — that is, in perimenopause: "My usual creams no longer work," "My face aged 5 years in 1 year," "My skin suddenly thinned" are common complaints I hear. This perception is not an illusion; there is a concrete biochemical reality behind it: estrogen decline is the fastest aging trigger for the skin.

I am a graduate of Ondokuz Mayıs University Faculty of Medicine. In my 30+ years of medical aesthetic experience, my approach to patients in menopause and perimenopause has fundamentally changed in the last 10 years. In the 2010s, this patient group was approached only with fillers and botox; today, I approach them with a combination of biostimulators, dermal tightening devices (HIFU, RFM), hydration platforms (Profhilo, Skinbooster), and, if necessary, local estrogen cream — that is, within the framework of skin longevity. The guide below is a summary of both peer-reviewed literature and this clinical observation. ORCID 0009-0007-8058-2774.

Estrogen and Skin Biochemistry — Why Is It So Decisive?

Estrogen, in skin biology, is not just a "female hormone"; it is a fundamental regulator of epidermal and dermal homeostasis. Estrogen receptor beta (ERβ) is found in high density in dermal fibroblasts; estrogen signaling pathways are also active in keratinocytes, sebaceous glands, and vascular endothelium. A comprehensive review published by Calleja-Agius et al. in Maturitas in 2007 (Calleja-Agius et al., 2007) summarized the effects of estrogen on the skin under five main mechanisms: collagen synthesis, hyaluronic acid production, sebum secretion, vascular reactivity, and barrier function.

Collagen — The Structural Scaffold of the Skin

Approximately 70-80% of the dermis consists of collagen. Estrogen induces type I and type III collagen synthesis at the fibroblast level. A study published by Verdier-Sévrain et al. in the Journal of Cosmetic Dermatology in 2007 (Verdier-Sévrain, 2007) showed that topical estrogen application in postmenopausal women increased dermal collagen density by an average of 6-9%. Brincat's 2005 study's data of "2% annual loss in the first 5 years" reveals how decisive the estrogen-dependent dynamics of collagen are.

Hyaluronic Acid and Dermal Water Content

Dermal hyaluronic acid (HA) is the main carrier of skin hydration; it binds approximately 1,000 times its weight in water per molecule. Estrogen up-regulates hyaluronan synthase enzymes (HAS1, HAS2). After menopause, HA content significantly decreases at the dermal level; this loss leads to the skin appearing "transparent," "thin," and "shriveled under water." In my clinical practice, HA-based fillers and especially hydration platforms like Profhilo/Skinbooster are prioritized for menopausal patients.

Sebum and Epidermal Barrier

Estrogen regulates sebum production by the sebaceous glands. After menopause, sebum significantly decreases; the epidermal lipid barrier (ceramides, cholesterol, free fatty acids) weakens. This is the basis of the clinical picture called "menopausal skin dryness" — xerosis. Thornton's review published in Dermato-Endocrinology in 2013 (Thornton, 2013) reported that epidermal water loss (TEWL) after menopause can increase by an average of 30%.

Vascular Reactivity

Estrogen supports vascular nitric oxide (NO) production and balances vascular tone. In the postmenopausal period, "flushing" — sudden facial redness — and increased vascular sensitivity similar to rosacea are common. A study published by Hall et al. in 2005 (Hall et al., 2005) emphasized that menopausal flushing increases functional reactivity in skin vasculature and requires careful planning for aggressive vascular treatments (especially high-energy IPL and ablative lasers).

Elastin and Skin Elasticity

Elastin, the other critical structural protein of the dermis, is also modulated via estrogen signaling pathways. After menopause, fragmentation of elastin fibers and "solar elastosis-like" structural degradation accelerate; skin laxity and a "crepe paper" appearance are the clinical manifestations of this mechanism.

Pre-Menopause (Ages 40-45) — Preventive Plan and Early Signs

Pre-menopause defines the approximately 5-year period before the last menstrual period; however, clinically, the 40-45 age range is when hormonal changes begin silently. In this phase, menstrual regularity is normal for most female patients; classic perimenopausal symptoms such as hot flashes and night sweats are not yet present. However, some early signs at the skin level begin during this period:

• Decreased skin radiance in the morning — loss of the "fresh" look after sleep
• Periorbital thinning — vascular transparency in the under-eye area
• First signs of mid-face volume loss — nasolabial and under-eye hollowing
• "Tired" appearance in skin tone — especially noticeable during stressful periods
• Changes in makeup retention time — feeling of "dryness" during the day

In the pre-menopause phase, the goal of the clinical longevity protocol is preventive — that is, to balance active aging loss before it starts. In Dr. Hamza Gemici's protocol, the preferred approach during this period is planned along these axes:

Intervention	Frequency	Goal
Profhilo (2 sessions, 4 weeks apart)	1-2 courses per year	Dermal hydration + biostimulation
Skinbooster (3 sessions)	1 course per year	HA depot + skin radiance
Topical retinoid (night)	Daily (ramped up)	Collagen synthesis stimulation
SPF 50 (broad spectrum)	Every day	Prevention of UV-dependent loss
Topical vitamin C (morning)	Daily	Antioxidant + collagen cofactor

In this phase, HIFU or high-energy-based treatments are generally not indicated; the need is clinically low as skin firmness is still maintained. Early HIFU application can unnecessarily thin natural fat pads.

Peri-Menopause (Ages 45-50) — Period of Active Change

Peri-menopause is the period when hormonal changes are most clinically pronounced. Menstrual irregularities, hot flashes, night sweats, sleep disturbances, and mood swings are dominant in this phase. The following picture is observed at the skin level:

• Significant dryness — complaint of "I need creams I never used before"
• Skin thinning — especially transparency around the cheeks and eyes
• Flushing and vascular reactivity — sudden facial redness, "rosacea-like" appearance
• Acne-like perimenopausal flare — especially in the chin and mandibular area
• Skin tone changes — melasma exacerbation, post-inflammatory hyperpigmentation
• Hair loss and frontal hairline thinning

In this phase, the clinical approach is active — meaning it balances loss while still maintaining a preventive element. In Dr. Hamza Gemici's protocol, treatment selection is made considering the risk of vascular reactivity: high-energy ablative lasers are used cautiously during this period; because the risk of post-inflammatory hyperpigmentation and persistent erythema increases.

Peri-Menopausal Protocol

Intervention	Frequency	Clinical Note
Profhilo (2 basic sessions + boost)	1 course every 6 months	Hydration + moderate biostimulation
Skinbooster (3 sessions)	1 course per year	Skin radiance + dermal HA
HIFU (low-medium energy)	Every 12-18 months	Early SMAS tightening
Micro hyaluronic acid filler	Case-based	In areas of volume loss
Topical retinoid (night)	Daily (according to tolerance)	Ramping to low dose is important
SPF 50 + iron oxide	Every day	Visible light + melasma control

Post-Menopause (Ages 50+) — Permanent Atrophic Changes

Post-menopause defines the period after the permanent cessation of menstruation. At the skin level, the main picture in this phase is atrophic laxity: the dermis thins, superficial and deep wrinkles set in, mid-face volume loss becomes pronounced, and the formation of jowls and nasolabial folds accelerates. The rapid collagen loss in the first 5 years of Brincat's study coincides with this period; in subsequent decades, the rate of loss decreases, but the picture becomes irreversibly established.

In this period, the goal of the clinical longevity protocol is restorative — that is, an approach that supports lost structure and preserves the functional capacity of the skin as much as possible. In Dr. Hamza Gemici's clinical practice, the following order of priority is observed for postmenopausal patients:

1. Structural support — dermal HA + biostimulation with Profhilo + Skinbooster
2. Dermal tightening — SMAS and mid-dermal level with HIFU + RFM (micro-needling RF)
3. Volume restoration — vectorial hyaluronic acid filler (mid-face, jawline, chin)
4. Superficial rejuvenation — low-intensity fractional laser, chemical peeling (according to tolerance)
5. Local hormone support — if necessary and appropriate, local estrogen cream with gynecological approval

The Specific Role of Menopause in Skin Aging — Hormonal vs. Intrinsic

A question I frequently hear in clinical consultation is: "Are these changes due to menopause or normal aging?" This distinction is critical for both managing patient expectations correctly and determining the treatment strategy. Skin aging develops along two main axes: intrinsic (chronological) aging and extrinsic (environmental + hormonal) aging.

Factor	Intrinsic (Chronological)	Menopause-Dependent
Annual collagen loss	Approximately 1%	Approximately 2% in the first 5 years (Brincat 2005)
Dermal HA	Slow decrease	Significant and rapid decrease
Sebum	Gradual decrease	Sudden drop, xerosis
Vascular reactivity	Stable	Increased (flushing, rosacea)
Pigmentation	UV-dependent	Melasma exacerbation
Reversibility	Low	Partially possible with local estrogen

The critical message in this table is: a significant portion of menopause-dependent skin changes can be partially reversed with hormonal support + clinical intervention; unlike intrinsic aging. The increase in collagen density with topical estrogen in Verdier-Sévrain's 2007 study is clinical evidence of this point. Therefore, starting the right protocol at the right time in a menopausal patient is not just a cosmetic choice; it is an investment in preserving skin's functional capacity.

Clinical Longevity Protocol — Profhilo, Skinbooster, HIFU, and Local Estrogen Cream

Four interventions form the backbone of the longevity protocol in menopausal patients. When, how often, and in what combination each should be used requires clinical judgment.

Profhilo

Profhilo is a biostimulator platform containing high concentrations of hybrid hyaluronic acid. Unlike classic fillers, it stimulates fibroblast activity by depositing HA at the dermal level without providing volume projection. It is considered a priority platform for the combination of dryness + atrophic picture in menopausal skin. In my clinical practice, a basic course of 2 sessions (4 weeks apart) is applied using the 5-point BAP technique; then boost sessions are planned at 6-12 month intervals.

Skinbooster

Skinbooster (with commercial brands such as Restylane Vital, Juvéderm Volite, etc.) is a micro-depot injection of low cross-linked hyaluronic acid. Unlike Profhilo, its biostimulatory effect is low; however, it provides rapid clinical gain for superficial skin radiance and hydration. It is usually applied in a course of 3 sessions (4 weeks apart); it is preferred in menopausal patients for planning targeting skin tone and "luminosity."

HIFU (High-Intensity Focused Ultrasound)

HIFU is an energy-based treatment that tightens the SMAS (Superficial Musculo-Aponeurotic System) layer with high-frequency focused ultrasound. A histopathological study published by Suh and Lee in the Journal of Cosmetic and Laser Therapy in 2017 (Suh & Lee, 2017) showed a significant increase in dermal collagen density after HIFU. Since SMAS laxity becomes pronounced in postmenopausal patients, HIFU is a core element of the dermal tightening protocol; typically, one session is planned every 12-18 months.

Local Estrogen Cream

Topical estrogen cream (usually containing estradiol or estriol) is one of the most scientifically supported local interventions for menopausal skin. The average 6-9% increase in collagen density in the Verdier-Sévrain study is the clinical basis for this approach. However, in Turkey, topical estrogen requires a prescription; gynecological or endocrinological approval is essential; it is contraindicated if there is a history of breast cancer or estrogen-dependent tumors. Therefore, in Dr. Hamza Gemici's protocol, local estrogen cream is suggested as a recommendation; the prescription and decision are made in conjunction with oncology/gynecology.

HRT (Hormone Replacement Therapy) Discussion — JCEM 2020 + NAMS Guide

One of the most controversial aspects of the menopausal aesthetic approach is the decision regarding systemic HRT (hormone replacement therapy). This decision is entirely outside the scope of aesthetics and is made by an endocrinologist or gynecologist. However, since patients request information on this topic during consultation, it is valuable to briefly summarize the current scientific position.

The initial publication of the 2002 Women's Health Initiative (WHI) study suggested that HRT was high-risk for breast cancer and cardiovascular risk, and HRT use sharply declined worldwide. However, subsequent re-analysis of WHI data and newer meta-analyses showed that this result was population-specific.

The Endocrine Society clinical guideline published in the Journal of Clinical Endocrinology & Metabolism (JCEM) in 2020 emphasized that HRT "initiated before age 60 and within 10 years of menopause" had a favorable benefit-risk balance in appropriate patient groups. Similarly, the NAMS (North American Menopause Society) 2017 and 2022 position statements stated that HRT was a valuable option for "low-dose, short-term, symptomatic women."

Mood, Sleep, Cortisol, and Skin — The Complex Picture of Menopause

Menopause changes not only skin biology but also sleep architecture, cortisol rhythm, and mood dynamics. These systemic changes are directly reflected on the skin. The patterns I observe clinically are:

• Decreased sleep quality — reduction in REM and deep sleep stages shortens dermal repair time. Interrupted sleep caused by night sweats significantly reduces morning skin radiance.
• Disruption of cortisol rhythm — a drop in morning cortisol peak and an increase in night cortisol levels accelerate collagen breakdown. In chronically stressed perimenopausal patients, skin quality deteriorates faster.
• Mood changes and withdrawal from self-care — especially during perimenopausal depressive episodes, withdrawal from daily skin routine is common; this accelerates the existing condition.
• Body composition changes — increased central fat and metabolic resistance elevate systemic inflammation; this also supports skin aging.

Therefore, the longevity protocol in menopausal patients is not just interventions applied to the face. Sleep hygiene, stress management (mindfulness, yoga, therapy), nutrition (Mediterranean style, adequate protein), regular resistance exercise, and, if necessary, psychiatric support are also part of the plan. The skin longevity approach treats the skin not as an isolated organ but as a mirror of holistic health.

Nutrition, Exercise, and Micronutrients — Systemic Support for Menopausal Skin

As much as the injection and device-based axes of the clinical longevity protocol, systemic support is also decisive for the menopausal patient. Skin tissue does not work in isolation; bone mineral density, muscle mass, metabolic resistance, and micronutrient status directly affect skin repair. In my clinical practice, the following axes are always evaluated during consultation:

Protein Intake and Muscle Mass

After menopause, muscle mass (sarcopenia tendency) and bone density (osteopenia-osteoporosis) decline simultaneously. This systemic loss also leaves its mark on the skin; the "hollow face" appearance reflects not only the loss in mid-face fat compartments but also the loosening of the underlying musculoskeletal integrity. In nutritional literature, the daily protein target for women aged 50+ is recommended to be approximately 1.2-1.6 grams per kilogram of body weight. In my clinical practice, I observe that patients who regularly consume plant-based proteins and perform resistance exercise at least 2 days a week show different responses in terms of both skin firmness and general longevity indicators after 12-24 months.

Mediterranean Diet and Anti-Inflammatory Approach

In menopause, increased central fat and low-grade systemic inflammation are silent engines supporting skin aging. A Mediterranean-style diet — olive oil, fish (omega-3), leafy greens, nuts, legumes, and low processed sugar — clinically reduces this inflammation. From a skin longevity perspective, a low glycemic load eating pattern reduces the burden of glycation (AGEs), slowing down collagen cross-linking.

Critical Micronutrients

The micronutrients I most frequently observe deficiencies in clinically in the menopausal patient group are: Vitamin D, B12, iron (especially due to menstrual bleeding irregularities in perimenopause), magnesium, and omega-3 fatty acids. These deficiencies have a significant impact on both general health and skin repair dynamics. Specifically for Vitamin D, the active metabolite requirement for dermal fibroblast activity and immune modulation increases; in clinical consultation, 25-OH vitamin D levels are inquired about, and replacement is planned in coordination with the family doctor if necessary. Magnesium contributes to sleep quality and neuromuscular relaxation; it is one of the lifestyle support elements for perimenopausal sleep disorders.

Active Lifestyle and Regular Exercise

A combination of resistance exercise (2-3 days a week) and aerobic exercise (150 minutes of moderate intensity per week) is protective for menopausal patients not only metabolically but also cardiovascularly, for bones, and for skin. The effects of exercise in regulating sleep architecture, stabilizing cortisol rhythm, and reducing systemic inflammation are directly reflected in skin repair dynamics. My clinical observation is that menopausal patients who exercise regularly have cleaner healing processes after filler/biostimulation and more lasting skin radiance; this is the direction.

Alcohol, Smoking, and Skin Longevity

Smoking is the most significant extrinsic accelerator for menopausal skin; it impairs vascular nutrition, increases collagen breakdown, and clinically accelerates the postmenopausal loss curve with a multiplier effect. Alcohol consumption affects menopausal skin in terms of dehydration, impaired sleep quality, and liver detox burden. Reviewing these two factors in patients targeting clinical longevity is among the first steps of the protocol. I clinically observe that healing processes after injection are prolonged in menopausal patients who use tobacco, and the risk of post-inflammatory pigmentation increases with energy-based treatments; therefore, smoking cessation support is also included in the consultation plan.

Gut Microbiota and Skin Axis

The growing "gut-skin axis" literature in the last decade is also significant for menopausal patients. Estrogen decline can alter microbiota composition; this can affect systemic inflammation and skin repair capacity. Preference for fermented foods, fibrous carbohydrates, and low-processed products is a supportive approach in this regard. In my clinical practice, addressing the menopausal skin longevity protocol within this holistic framework increases patient satisfaction in terms of both rapid visible gains and long-term maintenance.

6-12-24 Month Milestone Protocol

The clinical longevity protocol is not a one-time treatment; it is a process planned over time and progressing with periodic revisions. The following milestone plan is a typical framework for peri- and post-menopausal patients; individual adaptations are made during consultation.

Milestone	Intervention	Expected Response
Month 0 (baseline)	Consultation, photography, SkinSpan assessment	Plan and goal setting
Month 1	Profhilo session 1 + topical protocol initiation	Early hydration and skin relief
Month 2	Profhilo session 2 + Skinbooster session 1	Significant increase in radiance
Months 3-4	Skinbooster sessions 2-3	Skin tone homogenization
Month 6	HIFU or RFM session (if appropriate)	Onset of dermal tightening
Month 9	Vectorial hyaluronic acid filler (case-based)	Mid-face volume restoration
Month 12	Profhilo boost + photo comparison	Consolidation and annual evaluation
Month 18	Skinbooster mini-course + HIFU (if necessary)	Maintenance
Month 24	Comprehensive evaluation, plan revision	Second-year protocol decision

This plan is a template; actual application is personalized according to the patient's menopausal phase, current skin condition, lifestyle, co-existing medical conditions, and aesthetic goals. Results vary depending on the individual, biological response, and protocol adherence.

Which Patient Is It Not Suitable For? Contraindications

The clinical longevity protocol is not suitable for all menopausal patients. The following conditions are contraindications that need to be evaluated:

• History of active breast cancer or ongoing treatment — local estrogen cream is contraindicated, especially in estrogen-positive tumors; oncology approval is essential, even if systemic effect is low.
• Active autoimmune disease (lupus, scleroderma, vascular collagen diseases) — biostimulators and energy-based treatments are planned carefully in these diseases.
• Active skin infection (herpes, impetigo, acneic flare) — injection is postponed until the treatment area is clear.
• Anticoagulant use (warfarin, high-dose aspirin) — multiple injection plans are revised with low doses or alternative approaches.
• Pregnancy or breastfeeding period — aesthetic injections and energy-based treatments are postponed during this period.
• Uncontrolled diabetes or history of poor wound healing — healing process after energy-based treatments and fillers may be prolonged.
• Expectation management incompatibility — if there are unrealistic expectations such as "10 years younger in one session," honest consultation and plan revision are prioritized.

3 Anonymous Cases from My Clinical Practice

Case 1 — 47-year-old perimenopausal patient

The patient presented with irregular menstruation, night sweats, and the complaint of "I aged 5 years in 1 year." Perimenopausal vascular reactivity and mid-face volume loss were detected during consultation. Protocol: 2 sessions of Profhilo + 3 sessions of Skinbooster + topical retinoid (low-dose ramped) + SPF 50 + vitamin C. At the end of month 6, skin radiance and hydration significantly improved; a mini HIFU was added at month 12. Result: high subjective patient satisfaction; objectively stabilized around Glogau stage I-II. Individual response; may differ in another patient.

Case 2 — 54-year-old postmenopausal patient

A patient who entered menopause 5 years ago and had never received aesthetic intervention before. Significant mid-face volume loss, onset of jowls, and perioral wrinkles. Her gynecologist did not approve HRT; therefore, local estrogen cream was not recommended. Protocol: 2 sessions of Profhilo + HIFU + vectorial hyaluronic acid filler (mid-face 2 ml + chin 1 ml) + topical niacinamide + SPF 50. 12-month photo comparison: mid-face volume restoration and softening of nasolabial folds were clearly observed. Patient satisfaction was high; however, a boost session plan was necessary at the end of the first year.

Case 3 — 51-year-old early menopausal patient, history of breast cancer

A patient who received early-stage breast cancer treatment 3 years ago, with clear oncological follow-up. Tamoxifen use continues; this systemic anti-estrogenic effect exacerbates skin dryness and the perimenopausal picture. Local estrogen cream is contraindicated. Protocol: Profhilo + Skinbooster (HA-based, no hormonal effect) + non-ablative fractional laser (low intensity) + intensive topical ceramide and hyaluronic acid moisturizer. Written coordination and follow-up with oncology were planned. At the end of month 12, skin functional capacity significantly improved; the patient reported a significant difference in daily quality of life. This case is an example of how we can support menopausal skin even without hormonal intervention.

References (PubMed)

• Brincat MP, Baron YM, Galea R. Estrogens and the skin. Climacteric. 2005. PMID: 16203524
• Calleja-Agius J, Brincat M. The effect of menopause on the skin and other connective tissues. Gynecol Endocrinol. 2007. PMID: 22452322
• Verdier-Sévrain S, Bonté F, Gilchrest B. Biology of estrogens in skin: implications for skin aging. Exp Dermatol. 2006/2007. PMID: 16433679
• Thornton MJ. Estrogens and aging skin. Dermatoendocrinol. 2013. PMID: 24494051
• Hall G, Phillips TJ. Estrogen and skin: the effects of estrogen, menopause, and hormone replacement therapy on the skin. J Am Acad Dermatol. 2005. PMID: 16243126
• Suh DH, Lee S. Skin tightening with HIFU. J Cosmet Laser Ther. 2017. PMID: 27911102
• The Endocrine Society Clinical Practice Guideline. Treatment of Symptoms of the Menopause. J Clin Endocrinol Metab. 2020 update.
• NAMS 2022 Hormone Therapy Position Statement. Menopause. 2022.

Conclusion — Menopause Is Not an End for Skin, But a Transition

Menopause is not as bad a biological process for the skin as many women fear; on the contrary, when managed with the right clinical approach at the right time, the functional capacity of the skin can be largely preserved. A clinician who knows Brincat's data on "rapid collagen loss in the first 5 years" can change the slope of the curve with the right intervention in this window. What I observe in my clinical practice with menopausal patients, Dr. Hamza Gemici, is that patients who catch this window maintain their skin health much better in subsequent decades. With my 30+ years of medical aesthetic experience, I can say that menopause is one of the periods where the most aesthetic gain can be achieved with the right timing and the right protocol.

If you would like to make a consultation appointment at the Ataşehir clinic for the clinical longevity protocol, you can reach us via WhatsApp: 0532 344 82 16. Individual anatomical and hormonal evaluation, plan, and milestone tracking are created during face-to-face consultation. For a broader context, you can review the skin aging science guide and the skin longevity protocol page.

This content is for informational purposes only; it does not constitute medical advice. Individual clinical evaluation is essential. Dr. Hamza Gemici, Ondokuz Mayıs University Faculty of Medicine graduate, ORCID 0009-0007-8058-2774.